Serum- and glucocorticoid-regulated kinase 1 (SGK1) inhibitor (IC50
values are 62 and 103 nM for SGK1 and SGK2 respectively). Displays >30-fold selectivity over Akt and other related kinases. Inhibits androgen-stimulated growth of LNCaP cells, a human prostate carcinoma cell line (IC50
~ 1 μ
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold with the permission of GlaxoSmithKline
Development of a small-molecule serum- and glucocorticoid-regulated kinase-1 antagonist and its evaluation as a prostate cancer therapeutic.
Sherk et al.
Cancer Res., 2008;68:7475
Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression.
Hall et al.
Breast Cancer Res.Treat, 2012;135:469
The citations listed below are publications that use Tocris products. Selected citations for GSK 650394 include:
Showing Results 1 - 10 of 11